Weekly Recap | XLV.US +1.83%, outpacing the S&P by nearly two points
I'm LongbridgeAI, I can summarize articles.XLV.US gained 1.83% this week, closing at $168.39 compared with $165.36 the previous Friday. The S&P 500 fell 0.08% over the same period, so the fund outperformed by about 1.91 percentage points. The week was mildly choppy with an upward tilt. Monday opened at $168.01 and settled at $167.75. Tuesday slipped to a $166.18 low before closing at $167.66. Wednesday held a narrow range. Thursday pushed up to $169.10 and finished at $168.81. Friday pulled back slightly to close at $168.39.
The Week
XLV.US gained 1.83% this week, closing at $168.39 compared with $165.36 the previous Friday. The S&P 500 fell 0.08% over the same period, so the fund outperformed by about 1.91 percentage points. The week was mildly choppy with an upward tilt. Monday opened at $168.01 and settled at $167.75. Tuesday slipped to a $166.18 low before closing at $167.66. Wednesday held a narrow range. Thursday pushed up to $169.10 and finished at $168.81. Friday pulled back slightly to close at $168.39. Weekly amplitude was 1.74%, a relatively calm range. The latest price sits below the 20-day moving average of $170.29, but above the 60-day average of $165.79.
Sector News
Healthcare news this week was dominated by large-cap clinical readouts, regulatory decisions and capital moves. Amgen’s Imdelltra won FDA approval for shorter monitoring time on the first two doses, and UBS initiated coverage with a buy rating. Johnson & Johnson reported lung cancer drug data showing fewer side effects and longer survival, while TECVAYLI received a positive CHMP recommendation. Merck’s Keytruda combination got a favourable EU CHMP opinion for bladder cancer. AbbVie released real-world data on Vraylar. Abbott agreed to a $384 million settlement with the Department of Justice over infant formula contamination and declared a $0.63 dividend. Gilead and PAHO struck a deal to accelerate lenacapavir access for HIV prevention. Thermo Fisher called 2026 an outstanding year. The sector showed a mix of regulatory momentum and isolated pipeline setbacks, including a failed mid-stage depression trial for a J&J partner.
The Week Ahead
On 22 September, the Richmond Fed composite index (previous: 4) will offer a read on regional manufacturing conditions. On 24 September, initial jobless claims (previous: 196) and new home sales (previous: 0.607 million, forecast 0.608 million) arrive. Labour market and housing data could shift rate expectations and ripple through long-duration assets like healthcare ETFs. Energy inventory data on 23-24 September also matters indirectly, since oil price swings can alter overall risk appetite.
In Short
XLV.US rose 1.83% this week and beat the S&P 500 by nearly two percentage points, but a 1.74% weekly amplitude and a close below the 20-day moving average suggest cautious participation. Valuation is moderate at 16.91x P/E, 1.31x P/B and a 1.50% dividend yield. On the latest trading day, large and medium orders net sold roughly $35.4 million while small orders showed little selling pressure, leaving a mixed funding picture. The sector had its share of regulatory and clinical wins for Amgen, J&J and Merck, alongside pipeline disappointments. What matters next is whether macro data shifts rate expectations and whether healthcare can reclaim its 20-day average.
This article is generated by LongbridgeAI from market data, for information only and not investment advice.